IRWD - Ironwood Pharmaceuticals Inc Stock Price, Fair Value and News

7.59USD-0.06 (-0.78%)Market Closed

Market Summary

USD7.59-0.06

Market Closed

-0.78%

IRWD Stock Price

View Fullscreen

IRWD RSI Chart

IRWD Valuation

Market Cap

1.2B

Price/Earnings (Trailing)

-1.19

Price/Sales (Trailing)

2.68

EV/EBITDA

-1.4

Price/Free Cashflow

6.49

IRWD Price/Sales (Trailing)

IRWD Profitability

Operating Margin

95.58%

EBT Margin

-214.14%

Return on Equity

289.42%

Return on Assets

-212.76%

Free Cashflow Yield

15.42%

IRWD Fundamentals

IRWD Revenue

Revenue (TTM)

442.7M

Rev. Growth (Yr)

9.66%

Rev. Growth (Qtr)

3.35%

IRWD Earnings

Earnings (TTM)

-1.0B

Earnings Growth (Yr)

-102.22%

Earnings Growth (Qtr)

-107.09%

Breaking Down IRWD Revenue

Last 7 days

-4.0%

Last 30 days

-9.9%

Last 90 days

-37.0%

Trailing 12 Months

-29.9%

How does IRWD drawdown profile look like?

IRWD Financial Health

Current Ratio

0.84

Debt/Equity

-0.57

Debt/Cashflow

0.92

IRWD Investor Care

Shares Dilution (1Y)

1.54%

Diluted EPS (TTM)

-6.51

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	417.1M	427.3M	432.4M	442.7M
2022	422.4M	415.6M	420.5M	410.6M
2021	398.4M	413.0M	413.3M	413.8M
2020	439.6M	426.8M	399.1M	389.5M
2019	343.0M	364.1M	436.0M	428.4M
2018	315.3M	331.3M	303.8M	343.4M
2017	260.1M	270.8M	291.5M	298.3M
2016	186.7M	213.3M	239.8M	274.0M
2015	90.8M	111.7M	134.3M	149.6M
2014	34.2M	31.4M	43.4M	76.4M
2013	118.4M	86.6M	54.7M	22.9M
2012	67.9M	71.2M	155.4M	150.2M
2011	45.3M	47.3M	50.5M	65.9M
2010	36.7M	39.1M	41.5M	43.9M
2009	0	0	0	34.3M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Ironwood Pharmaceuticals Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 15, 2024	denner alexander j	acquired	-	-	1,662	-
Mar 08, 2024	john minardo	acquired	-	-	32,752	chief legal officer
Mar 08, 2024	davis andrew	acquired	-	-	37,120	svp, chief business officer
Mar 08, 2024	shetzline michael	acquired	-	-	34,936	cmo,svp,head-res&drug
Mar 08, 2024	mccourt thomas a	acquired	-	-	120,298	chief executive officer
Mar 08, 2024	emany sravan kumar	acquired	-	-	37,120	svp, chief financial officer
Mar 06, 2024	duane jon r	bought	60,204	8.7	6,920	-
Mar 05, 2024	mccourt thomas a	acquired	-	-	264,876	chief executive officer
Mar 04, 2024	emany sravan kumar	bought	100,216	9.38	10,684	svp, chief financial officer
Feb 12, 2024	silver ronald	sold	-120,518	15.24	-7,908	principal accounting officer

Which funds bought or sold IRWD recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 17, 2024	Hennion & Walsh Asset Management, Inc.	reduced	-0.77	-31,536	97,439	-%
Apr 17, 2024	GRIMES & COMPANY, INC.	reduced	-3.53	-118,881	328,881	0.01%
Apr 16, 2024	Hodges Capital Management Inc.	new	-	7,521,000	7,521,000	0.48%
Apr 16, 2024	SummerHaven Investment Management, LLC	added	1.15	-180,758	605,685	0.38%
Apr 15, 2024	EXCHANGE TRADED CONCEPTS, LLC	sold off	-100	-2,605,650	-	-%
Apr 12, 2024	AdvisorNet Financial, Inc	sold off	-100	-217	-	-%
Apr 11, 2024	City State Bank	unchanged	-	-	1,000	-%
Apr 10, 2024	Banque Cantonale Vaudoise	added	10.11	-12,000	63,000	-%
Apr 09, 2024	MASSMUTUAL TRUST CO FSB/ADV	reduced	-47.14	-957	645	-%
Apr 05, 2024	CWM, LLC	added	370	27,000	37,000	-%

Are Funds Buying or Selling IRWD?

Are funds buying IRWD calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own IRWD

No. of Funds

Unveiling Ironwood Pharmaceuticals Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 09, 2024	lsv asset management	4.35%	6,793,701	SC 13G/A
Jan 25, 2024	state street corp	7.39%	11,532,088	SC 13G/A
Jan 22, 2024	blackrock inc.	16.6%	25,978,899	SC 13G/A
Jan 10, 2024	vanguard group inc	10.27%	16,033,545	SC 13G/A
Jul 05, 2023	westfield capital management co lp	-	0	SC 13G/A
May 10, 2023	wellington management group llp	0.00%	0	SC 13G/A
Feb 14, 2023	brown capital management llc	2.61%	3,997,045	SC 13G/A
Feb 10, 2023	lsv asset management	5.17%	7,926,397	SC 13G
Feb 09, 2023	vanguard group inc	9.60%	14,732,569	SC 13G/A
Feb 06, 2023	wellington management group llp	8.70%	13,340,377	SC 13G/A

Recent SEC filings of Ironwood Pharmaceuticals Inc

View All Filings

Date Filed	Form Type	Document
Mar 19, 2024	4	Insider Trading
Mar 12, 2024	4	Insider Trading
Mar 12, 2024	4	Insider Trading
Mar 12, 2024	4	Insider Trading
Mar 12, 2024	4	Insider Trading
Mar 12, 2024	4	Insider Trading
Mar 08, 2024	4	Insider Trading
Mar 07, 2024	4	Insider Trading
Mar 06, 2024	4	Insider Trading
Feb 16, 2024	10-K	Annual Report

Peers (Alternatives to Ironwood Pharmaceuticals Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
JNJ	351.1B	85.2B	-7.62%	-10.06%	9.99	4.12	6.46%	95.94%
MRK	317.1B	60.1B	3.25%	9.20%	868.73	5.27	1.40%	-97.49%
PFE	143.3B	46.5B	-8.33%	-37.34%	-103.22	3.08	42.59%	-114.62%
AMGN	140.8B	28.2B	-2.53%	7.29%	20.96	4.99	7.09%	2.52%
GILD	82.4B	27.1B	-8.60%	-20.08%	14.54	3.04	-0.60%	23.36%
TEVA	14.3B	15.8B	-0.90%	54.57%	-24.85	0.9	6.17%	76.47%
MID-CAP
PRGO	4.1B	4.7B	0.13%	-17.24%	-320.54	0.87	4.58%	90.97%
ALKS	4.0B	1.7B	-12.75%	-17.88%	11.17	2.39	49.61%	324.78%
BHC	3.1B	8.8B	-7.68%	16.09%	-5.31	0.36	7.79%	-163.11%
AMPH	1.9B	644.4M	-6.53%	-6.23%	13.51	2.88	29.14%	50.51%
SMALL-CAP
TLRY	1.3B	743.2M	-10.42%	-30.36%	-3.8	1.8	24.65%	80.36%
TXMD	21.7M	1.3M	-17.83%	-48.08%	-2.11	16.65	-98.14%	-109.18%
ACRX	17.1M	-	-12.17%	23.93%	-0.93	0.22	2882.68%	-138.52%
AGRX	2.5M	19.6M	-33.93%	-94.71%	-0.18	0.13	80.00%	43.08%
ACOR	422.3K	117.6M	-96.45%	-95.94%	0	0	-0.79%	-283.60%

Ironwood Pharmaceuticals Inc News

Latest updates

Ironwood Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Quarterly)																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	3.4%	118	114	107	104	107	109	97.00	98.00	117	104	104	89.00	117	103	89.00	80.00	126	131	102	69.00	134
Costs and Expenses	8.5%	80.00	74.00	1,191	44.00	39.00	40.00	42.00	40.00	61.00	39.00	39.00	43.00	65.00	58.00	57.00	67.00	77.00	65.00	81.00	86.00	101
Operating Expenses	-	-	-	-	44.00	-	40.00	42.00	40.00	-	39.00	39.00	43.00	-	-	-	-	-	-	-	-	-
S&GA Expenses	7.3%	39.00	36.00	52.00	31.00	28.00	29.00	30.00	29.00	29.00	28.00	27.00	28.00	34.00	35.00	35.00	36.00	39.00	41.00	43.00	49.00	50.00
R&D Expenses	8.2%	36.00	33.00	35.00	13.00	10.00	12.00	11.00	11.00	32.00	11.00	12.00	15.00	16.00	22.00	22.00	28.00	27.00	28.00	29.00	32.00	20.00
EBITDA Margin	-1.5%	-2.09*	-2.06*	-2.01*	0.65*	0.64*	0.58*	0.57*	0.58*	0.56*	0.56*	0.50*	0.45*	-	-	-	-	-	-	-	-	-
Interest Expenses	-14.4%	8.00	10.00	2.00	2.00	2.00	2.00	2.00	2.00	8.00	8.00	8.00	8.00	8.00	7.00	7.00	7.00	7.00	10.00	9.00	10.00	10.00
Income Taxes	78.4%	32.00	18.00	13.00	20.00	23.00	20.00	17.00	18.00	5.00	4.00	-336	0.00	1.00	1.00	-	-	-	-	-	-	-
Earnings Before Taxes	-4.9%	30.00	32.00	-1,076	66.00	72.00	70.00	54.00	56.00	46.00	60.00	54.00	40.00	45.00	36.00	25.00	3.00	48.00	21.00	-	-	-
EBT Margin	-2.2%	-2.14*	-2.10*	-2.03*	0.63*	0.61*	0.54*	0.52*	0.51*	0.48*	0.48*	0.42*	0.37*	-	-	-	-	-	-	-	-	-
Net Income	-107.1%	-1.09	15.00	-1,062	46.00	49.00	50.00	37.00	39.00	41.00	56.00	391	40.00	43.00	34.00	25.00	3.00	48.00	21.00	12.00	-59.28	-15.49
Net Income Margin	-2.8%	-2.26*	-2.20*	-2.21*	0.44*	0.43*	0.40*	0.42*	1.25*	1.28*	1.28*	1.23*	0.36*	-	-	-	-	-	-	-	-	-
Free Cashflow	9.9%	36.00	32.00	35.00	80.00	79.00	69.00	61.00	64.00	64.00	75.00	49.00	74.00	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-10.1%	471	524	603	1,155	1,101	1,040	976	1,083	1,127	1,079	1,007	599	559	492	444	404	403	334	316	324	332
Current Assets	-8.0%	233	254	318	866	781	699	618	710	745	695	620	538	496	433	374	334	307	258	221	202	266
Cash Equivalents	-16.3%	92.00	110	175	740	656	574	504	593	620	574	493	438	365	308	253	231	179	139	99.00	119	181
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.00	2.00	2.00	1.00	-
Net PPE	-0.8%	6.00	6.00	6.00	6.00	6.00	7.00	7.00	7.00	8.00	8.00	8.00	9.00	9.00	9.00	11.00	12.00	12.00	11.00	7.00	10.00	8.00
Goodwill	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.00	1.00	1.00	1.00	1.00
Current Liabilities	-1.6%	276	281	305	24.00	26.00	27.00	23.00	147	162	146	134	24.00	32.00	33.00	27.00	28.00	41.00	53.00	111	119	120
Long Term Debt	0.1%	198	198	198	397	396	396	395	395	337	333	329	436	430	425	419	413	408	403	274	270	266
LT Debt, Current	0.1%	200	199	199	-	-	-	-	121	117	115	113	-	-	-	-	-	-	-	-	-	-
LT Debt, Non Current	0.1%	198	198	198	397	396	396	395	395	337	333	329	436	430	425	419	413	408	403	274	270	266
Shareholder's Equity	-Infinity%	-346	-	-	707	652	591	533	518	606	580	512	110	63.00	6.00	-	-	-	-	-	-	-
Retained Earnings	-0.1%	-1,698	-1,697	-1,712	-650	-696	-745	-795	-832	-937	-978	-1,034	-1,426	-1,466	-1,509	-1,543	-1,568	-1,572	-1,620	-1,640	-1,650	-1,591
Additional Paid-In Capital	-1.4%	1,355	1,375	1,367	1,357	1,349	1,336	1,328	1,350	1,543	1,559	1,546	1,536	1,529	1,515	1,507	1,497	1,479	1,467	1,421	1,413	1,395
Shares Outstanding	0.1%	156	156	156	155	154	155	153	158	162	162	162	161	-	-	-	-	-	-	-	-	-
Minority Interest	100.0%	-	-2.46	-1.07	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Float	-	-	-	1,466	-	-	-	1,555	-	-	-	1,859	-	-	-	1,635	-	-	-	1,697	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	10.4%	35,834	32,459	34,963	80,171	79,182	69,092	61,365	64,124	64,568	75,065	48,568	73,694	51,513	53,632	20,088	43,603	27,580	34,767	-9,237	-42,385	9,273
Share Based Compensation	10.1%	8,704	7,906	8,264	7,131	7,291	7,067	6,601	6,089	6,090	6,206	4,589	5,396	10,008	7,712	7,091	6,364	5,486	5,520	6,337	13,934	9,947
Cashflow From Investing	81.5%	-4,188	-22,625	-999,492	-13.00	27.00	-66.00	-88.00	-9.00	-128	-	-	-	-28.00	-	-376	-1,438	-2,661	-3,077	-2,429	-2,977	17,488
Cashflow From Financing	32.1%	-50,904	-74,988	399,071	3,981	2,806	797	-150,283	-90,873	-18,587	6,164	5,662	2,211	3,524	670	2,397	11,955	6,447	8,633	-7,500	-8,765	4,849
Buy Backs	-	-	-	32,900	90,500	-	1,505	32,896	90,489	-	-	-	-	-	-	-	-	-	-	-	-	-

IRWD Income Statement

2023-12-31

Consolidated Statements of Income (Loss) - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Revenues:
Total revenues	$ 442,735	$ 410,596	$ 413,753
Costs and expenses:
Research and development	116,085	44,265	70,405
Selling, general and administrative	158,314	115,994	111,133
Restructuring expenses	18,317		(44)
Acquired in-process research and development	1,095,449
Total costs and expenses	1,388,165	160,259	181,494
Income (loss) from operations	(945,430)	250,337	232,259
Other income (expense):
Interest expense and other financing costs	(21,629)	(7,598)	(31,150)
Interest and investment income	18,971	9,501	726
Gain (loss) on derivatives	19	182	(1,178)
Other income (expense), net	(2,639)	2,085	(31,602)
Income (loss) before income taxes	(948,069)	252,422	200,657
Income tax (expense) benefit	(83,490)	(77,357)	327,791
Net income (loss)	(1,031,559)	175,065	528,448
Less: Net income (loss) attributable to noncontrolling interests	(29,320)
Net income (loss) attributable to Ironwood Pharmaceuticals, Inc.	$ (1,002,239)	$ 175,065	$ 528,448
Net income (loss) per share attributable to Ironwood Pharmaceuticals, Inc. stockholders - basic (in dollars per share)	$ (6.45)	$ 1.13	$ 3.26
Net income (loss) per share attributable to Ironwood Pharmaceuticals, Inc. stockholders - diluted (in dollars per share)	$ (6.45)	$ 0.96	$ 3.21
Weighted average shares used in computing net income (loss) per share attributable to Ironwood Pharmaceuticals, Inc. stockholders - basic (in shares)	155,435	154,366	162,245
Weighted average shares used in computing net income (loss) per share attributable to Ironwood Pharmaceuticals, Inc. stockholders - diluted (in shares)	155,435	186,312	164,418

IRWD Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 92,154	$ 656,203
Accounts receivable, net	129,122	115,458
Prepaid expenses and other current assets	12,012	7,715
Restricted cash		1,250
Total current assets	233,288	780,626
Restricted cash, net of current portion		485
Accounts receivable, net of current portion		14,589
Property and equipment, net	5,585	6,288
Operating lease right-of-use assets	12,586	14,023
Intangible assets, net	3,682
Deferred tax assets	212,324	283,661
Other assets	3,608	847
Total assets	471,073	1,100,519
Current liabilities:
Accounts payable	7,830	483
Accrued research and development costs	21,331	5,258
Accrued expenses and other current liabilities	44,254	16,700
Current portion of operating lease liabilities	3,126	3,065
Current portion of convertible senior notes	199,560
Note hedge warrants		19
Total current liabilities	276,101	25,525
Convertible senior notes, net of current portion	198,309	396,251
Operating lease obligations, net of current portion	14,543	16,599
Revolving credit facility	300,000
Other liabilities	28,415	9,766
Commitments and contingencies
Stockholders' equity (deficit):
Preferred stock, $0.001 par value, 75,000,000 shares authorized, no shares issued and outstanding
Class A Common Stock, $0.001 par value, 500,000,000 shares authorized and 156,354,238 shares issued and outstanding at December 31, 2023 and 500,000,000 shares authorized and 154,026,949 shares issued and outstanding at December 31, 2022	156	154
Additional paid-in capital	1,355,195	1,348,600
Accumulated deficit	(1,698,615)	(696,376)
Accumulated other comprehensive loss	(3,031)
Total stockholders' equity (deficit)	(346,295)	652,378
Total liabilities and stockholders' equity	$ 471,073	$ 1,100,519

About Ironwood Pharmaceuticals Inc

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.

CEO	Mr. Thomas A. McCourt
WEBSITE	ironwoodpharma.com
INDUSTRY	Pharmaceuticals
EMPLOYEES	219

Ironwood Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Ironwood Pharmaceuticals Inc? What does IRWD stand for in stocks?

IRWD is the stock ticker symbol of Ironwood Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Ironwood Pharmaceuticals Inc (IRWD)?

As of Wed Apr 17 2024, market cap of Ironwood Pharmaceuticals Inc is 1.2 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of IRWD stock?

You can check IRWD's fair value in chart for subscribers.

What is the fair value of IRWD stock?

You can check IRWD's fair value in chart for subscribers. The fair value of Ironwood Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Ironwood Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for IRWD so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Ironwood Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether IRWD is over valued or under valued. Whether Ironwood Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Ironwood Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for IRWD.

What is Ironwood Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Apr 17 2024, IRWD's PE ratio (Price to Earnings) is -1.19 and Price to Sales (PS) ratio is 2.7. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. IRWD PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Ironwood Pharmaceuticals Inc's stock?

In the past 10 years, Ironwood Pharmaceuticals Inc has provided -0.016 (multiply by 100 for percentage) rate of return.